Clinical commissioning policy statement: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

Document first published:
Page updated:
Topic:
Publication type:

Adalimumab is not recommended to be available as a treatment option through routine commissioning for refractory chronic non-bacterial osteomyelitis/osteitis (all ages).

Document

Policy statement: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

Policy statement: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

  • PDF
  • 57 KB
  • 6 pages

Document

Clinical priorities advisory group summary report: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

Clinical priorities advisory group summary report: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

  • PDF
  • 92 KB
  • 5 pages

Document

Clinical panel report: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

Clinical panel report: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

  • PDF
  • 30 KB
  • 2 pages

Document

Engagement report: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

Engagement report: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

  • PDF
  • 193 KB
  • 5 pages

Document

Equality and health inequalities impact assessment: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

Equality and health inequalities impact assessment: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

  • PDF
  • 60 KB
  • 8 pages